Grants8

Search for grants with us!

Keywords

You can filter by below criteria

Grants

Grants you might be eligible for

Grant Information Key Details Eligibility & Funding

The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional)

PAR-25-292

Programme: NIH Research Project Grant

This grant, The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional), aims to support innovative population-based research. Its core objective is to identify and characterize how work and occupation influence health outcomes and status, particularly among populations experiencing health and/or healthcare disparities. The grant is SECTOR-SPECIFIC, focusing on public health, social sciences, and healthcare research. It targets organizations conducting research within the U.S. and its territories (including Puerto Rico and the Trust Territory of the Pacific Islands). This is a recurring grant opportunity with multiple application cycles until early 2028, indicating an ongoing program context within the NIH's broader mission to reduce health disparities.

Funding

Up to None USD

Deadline

Oct. 5, 2027, 5 p.m.

Details

Occupational Safety and Health Education and Research Centers (T42)

RFA-OH-25-002

Programme: Centers for Disease Control and Prevention (CDC) / National Institute for Occupational Safety and Health (NIOSH) grant program

This grant, RFA-OH-25-002, is designed to establish or continue Education and Research Centers (ERCs) focused on occupational safety and health (OSH) training. The core objective is to ensure an adequate supply of qualified personnel to advance the OSH field and prevent work-related injuries and illnesses in the U.S. ERCs are academic institutions that provide interdisciplinary graduate and post-graduate training, research, continuing education, and outreach in core OSH disciplines like industrial hygiene, occupational health nursing, occupational medicine, and occupational safety. This grant is SECTOR-SPECIFIC, targeting the occupational safety and health and public health sectors. The primary target recipients are higher education institutions and related entities with a focus on OSH education and research. The geographic scope is national, covering the United States, with an emphasis on regional presence and impact across the HHS Federal Regions. Foreign organizations and foreign components of U.S. organizations are explicitly ineligible. Key filtering criteria for initial screening include being a higher education institution or a related nonprofit/government entity capable of providing graduate and post-graduate OSH training and research. The grant aims to address nationwide workforce needs in OSH. This is a recurring funding opportunity, a reissue of a previous RFA, with multiple application due dates extending through October 2028. It continues the long-standing NIOSH ERC program, which has supported OSH capacity building since 1977.

Funding

Up to 9000000.00 USD

Deadline

Oct. 26, 2028, 9 p.m.

Details

Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)

PAR-25-233

Programme: National Institutes of Health (NIH) Funding Opportunity Announcements

This grant, the Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed), aims to fund small research projects. Its core objective is to identify, develop, and test strategies for successfully integrating evidence-based health interventions into real-world settings. It also supports research on how to stop using ineffective or harmful practices and on developing new methods for this type of research. This funding opportunity is SECTOR-SPECIFIC, focusing primarily on the health sector, including public health and clinical practice. It is designed for a wide range of organizations, from educational institutions and nonprofits to small businesses and government entities. The geographic scope is broad, covering both U.S. organizations and non-U.S. (foreign) entities. Key filtering criteria for this grant are its focus on researching implementation strategies (not testing the interventions themselves), its small grant (R03) mechanism with a limited budget, and the explicit exclusion of clinical trials. This is a recurring funding opportunity with multiple application deadlines each year until early 2028, reflecting an ongoing commitment from the National Institutes of Health (NIH) to bridge the gap between health research and practice.

Funding

Up to 100000.00 USD

Deadline

Jan. 7, 2028, 5 a.m.

Details

Vet-LIRN Network Capacity-Building Project and Equipment Grants

PAR-23-202

Programme: Department of Health and Human Services / U.S. Food and Drug Administration (FDA)

This grant, PAR-23-202, aims to fund veterinary diagnostic laboratories within the Vet-LIRN network for projects and equipment. The core objectives include supporting the development and validation of new methods related to animal food safety and antimicrobial resistance (AMR), conducting short-term monitoring, developing AMR stewardship projects, contributing to Vet-LIRN's AMR monitoring, and supporting One Health initiatives (e.g., emerging diseases, emergency surge capacity). This is a SECTOR-SPECIFIC grant primarily targeting established veterinary diagnostic laboratories. While not explicitly stated, the funding body (U.S. FDA) implies a U.S. geographic scope.

Funding

Up to 2500000.00 USD

Deadline

April 16, 2028, 3:59 a.m.

Details

Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed)

PAR-25-326

Programme: National Institutes of Health (NIH)

This opportunity, the Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed), aims to provide investigators with direct, in-kind access to contract research/medical organizations (CROs/CMOs) and subject matter experts (SMEs) within the NINDS URGenT Network. The core objective is to support planning, manufacturing, and limited nonclinical therapeutic development efforts, as well as other IND-enabling activities, to rapidly advance precision therapeutics for ultra-rare neurological and/or neuromuscular diseases towards clinical trials. This grant is SECTOR-SPECIFIC, focusing intensely on HEALTHCARE and TECHNOLOGY within the specialized domain of ultra-rare genetic diseases and gene-based therapies. It targets investigators and organizations in the US that are developing gene-based or transcript-directed clinical therapeutic candidates. Key filtering criteria include having established proof-of-concept (POC) data and a clear need for pre-IND or IND-enabling support, with the explicit exclusion of clinical trials. This is a recurring funding opportunity with multiple application cycles available through January 2028, forming a continuous mechanism within the broader NINDS URGenT Network to address unmet medical needs for ultra-rare neurological disorders.

Funding

Up to None USD

Deadline

Jan. 31, 2028, 5 p.m.

Details

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)

PAR-25-158

Programme: National Institutes of Health (NIH) Funding Opportunity

This grant, PAR-25-158, aims to fund research focused on preventing Fetal Alcohol Spectrum Disorders (FASD) by reducing prenatal alcohol exposure, and developing interventions for individuals affected by FASD throughout their lives. It supports biomedical, behavioral, and social sciences research, with a strong preference for applications that include clinical trials. This is a SECTOR-SPECIFIC grant targeting organizations capable of conducting research in the health and social sciences, specifically related to alcohol exposure and developmental disorders. The grant is open to a very broad range of organization types including academic institutions, non-profits, for-profits (including small businesses), and various government entities, both domestic and international. It is a recurring funding opportunity with multiple application cycles available until its expiration date in November 2026, and is a reissue of a previous funding opportunity, indicating continuity in program objectives.

Funding

Up to 500000.00 USD

Deadline

Oct. 19, 2026, 10 p.m.

Details

VILNIUS TECH MERIT Project Re-/Up-skilling Scholarship Call

11262COMPETITIVE_CALLen

Programme: DIGITAL-2021-SKILLS-01-SPECIALISED

This scholarship aims to promote lifelong learning and skill development in advanced digital areas for European citizens. It targets individuals who have completed specific short-term digital skills courses at VILNIUS TECH, encouraging re-skilling and up-skilling, especially for those without a prior ICT education or early graduates. This is a SECTOR-SPECIFIC grant focused on digital skills.

Funding

Up to 1000.00 EUR

Deadline

May 1, 2026, 10 a.m.

Details

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)

PAR-25-353

Programme: National Institute of Mental Health (NIMH)

Grant Purpose and Target This grant, PAR-25-353, aims to accelerate innovative drug and device discovery and development for mental disorders. Its core objective is to advance preclinical development, early-stage human studies, and proof-of-concept (PoC) testing of new, rationally-based candidate agents or devices to treat mental illnesses. The grant explicitly targets academic institutions, the biotechnology industry, the biomedical device industry, and the pharmaceutical industry. It encourages the formation of multidisciplinary teams and public-private partnerships. There are no specific organizational size limits mentioned, but the nature of the research suggests medium to large research-capable entities. It is a SECTOR-SPECIFIC grant, focusing primarily on healthcare, pharmaceuticals, and biotechnology related to mental health. The geographic scope is strictly limited to organizations based in the United States. Foreign organizations are not eligible to apply, though foreign components within U.S. applications are allowed. Key filtering criteria for initial screening include being a U.S.-based entity involved in drug or device discovery/development for mental disorders, with an emphasis on novel interventions (not just analogs of existing treatments) and a willingness to engage in multidisciplinary collaborative research up to early human clinical trial phases. This grant is a recurring opportunity, a reissue of a previous program (PAR-22-144), with multiple application due dates occurring annually until October 2027, indicating an ongoing program context.

Funding

Up to None USD

Deadline

Oct. 25, 2027, 5 p.m.

Details

Open topic on modern information and forensic evidence analysis and on frontline policing

HORIZON-CL3-2025-01-FCT-01

Programme: Horizon Europe

This grant is an open topic within the Civil Security for Society program, designed to support projects that address new, upcoming, or unforeseen challenges and/or develop creative or disruptive solutions for improving modern information and forensic evidence analysis or frontline policing. It aims to enhance the capabilities of security practitioners in preventing, detecting, and investigating criminal and terrorist offenses. This is a sector-specific grant, primarily targeting entities within the law enforcement and civil security domains. The target recipients are mainly public authorities and potentially other organizations, with a mandatory requirement for Police Authorities to be actively involved. Geographically, the grant is open to organizations from EU Member States and Associated Countries. Key filtering criteria for initial screening are the mandatory involvement of at least two Police Authorities from different eligible countries and the focus on research and innovation within the specified areas. The grant is part of the Horizon Europe Work Programme 2025, indicating it is likely a recurring program.

Funding

Up to 3000000.00 EUR

Deadline

Nov. 12, 2025, midnight

Details

Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)

PAR-25-268

Programme: National Institutes of Health (NIH)

This grant, PAR-25-268, supports investigator-initiated, fully remotely delivered and conducted clinical trials designed to assess the efficacy or effectiveness of complementary and integrative health interventions. The core objective is to build a rigorous evidence base for these approaches, often utilizing mHealth tools or technologies. It targets a broad range of US-based organizations including higher education institutions, various types of nonprofits, for-profit organizations (including small businesses), and federal/local government entities. The grant is SECTOR-SPECIFIC, focusing on healthcare research, particularly complementary and integrative health interventions. The geographic scope for applicant organizations is limited to the United States. While the trials must be fully remote, participants are expected to be geographically distributed across the US, and potentially Canada (trials conducted outside the US or Canada are not responsive). A key filtering criterion is the absolute requirement for a clinical trial that involves no in-person contact between research staff and study participants. This is a recurring grant opportunity, reissued from a previous announcement, with multiple application submission windows available until its expiration date in November 2026.

Funding

Up to None USD

Deadline

Oct. 20, 2026, 10 p.m.

Details

Support to Civil Society Organisations in Albania in the field of Diversity, Equality and Inclusion, Good Governance, Justice, Freedom and Security and Gender Equality and Gender Based Violence

184589PROSPECTSEN

Programme: Not specified in grant materials.

This grant aims to support Civil Society Organisations in Albania. Its core objective is to foster initiatives in critical areas such as Diversity, Equality, and Inclusion, Good Governance, Justice, Freedom, and Security, and Gender Equality and Gender-Based Violence. This is a SECTOR-SPECIFIC grant, focusing primarily on social and governance issues. The target recipients are Civil Society Organisations of unspecified size, operating exclusively within Albania. Key filtering criteria include the organization type (Civil Society Organisation), geographic location (Albania), and thematic alignment with the specified social and governance fields. The grant's frequency is not specified in the provided materials, but it is part of an ongoing effort to support civil society development in the region.

Funding

Up to None EUR

Deadline

Sept. 4, 2025, 2 p.m.

Details

Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)

PAR-24-306

Programme: National Institutes of Health (NIH)

This grant aims to expand, improve, or transform the utility of mammalian cancer and tumor models specifically for translational research. The core objective is to ensure these models are robust representations of human biology, appropriate for testing clinically important questions, and provide reliable information that ultimately benefits patients. It targets research organizations of various types and sizes, including higher education institutions, nonprofits, for-profit organizations (including small businesses), and various government entities, both within the U.S. and internationally. This is a SECTOR-SPECIFIC grant, focusing exclusively on oncology and cancer translational science. Key filtering criteria include the explicit focus on translational research using mammalian cancer models, and importantly, the grant is 'Clinical Trial Not Allowed', meaning applications proposing clinical trials will not be considered. Purely mechanistic research or the development of models for non-clinical research are also explicitly excluded. This is a recurring grant opportunity, as it is a reissue of a previous funding announcement, with multiple application deadlines extending through 2026.

Funding

Up to 499000.00 USD

Deadline

July 5, 2026, 5 p.m.

Details

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

PAR-25-059

Programme: Innovation Grants to Nurture Initial Translational Efforts (IGNITE)

This grant, part of the 'Innovation Grants to Nurture Initial Translational Efforts (IGNITE)' suite, aims to accelerate the development of new treatments for neurological or neuromuscular disorders. It specifically funds early-stage translational research focused on developing in vitro, ex vivo, or in vivo assays and conducting iterative screening to identify and characterize potential therapeutic agents. This is a SECTOR-SPECIFIC grant, exclusively targeting the healthcare/biotechnology sector, specifically in neuroscience and drug discovery. Eligible applicants are diverse, ranging from academic institutions and non-profits to small and large for-profit organizations, and various government entities. Key filtering criteria for initial screening: Your project must focus on neurological or neuromuscular disorders, involve assay development and therapeutic agent identification through screening, and explicitly not propose clinical trials or late-stage therapeutic optimization. The geographic scope is US and international. The grant is offered through a recurring program with multiple application deadlines each year, indicating ongoing commitment to this research area.

Funding

Up to 750000.00 USD

Deadline

Oct. 20, 2027, 5 p.m.

Details

Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional)

PAR-25-067

Programme: National Institutes of Health (NIH) - National Institute of Mental Health (NIMH) Research Project Grant

This grant, the 'Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional),' from the National Institute of Mental Health (NIMH), aims to fund research that explores the connection between social disconnection (like isolation and loneliness) and suicidal thoughts and behaviors in older adults. The main goal is to identify the underlying neurobiological, behavioral, and environmental mechanisms that contribute to this risk or offer protection against it. This information is intended to help develop better prevention and intervention strategies. This is a SECTOR-SPECIFIC grant, focusing primarily on Mental Health and Public Health Research related to aging. It targets research organizations capable of conducting rigorous scientific studies. The geographic scope includes organizations within the United States and international (non-U.S.) entities. This is a recurring funding opportunity, building upon previous announcements.

Funding

Up to None USD

Deadline

June 5, 2026, 5 p.m.

Details

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

PAR-25-060

Programme: Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program

This grant, part of the 'Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program', aims to foster the development and validation of animal models and human/animal tissue ex vivo systems. These models must accurately reflect the characteristics of specific neurological or neuromuscular disorders to significantly improve their relevance for future neurotherapeutic discovery. The grant is SECTOR-SPECIFIC, focusing exclusively on the healthcare and biomedical research sectors, particularly neuroscience and drug discovery. It targets a wide range of organizations involved in research, including academic institutions, non-profits, for-profits (including small businesses), and various government entities in the U.S. and internationally. The key filtering criteria are the grant's explicit focus on model development and validation for neurological/neuromuscular diseases, with clinical trials not allowed. It also requires a phased approach (R61/R33) with clear milestones. This is a recurring funding opportunity with multiple application cycles available until October 2027, reissuing a previous call.

Funding

Up to 750000.00 USD

Deadline

Oct. 20, 2027, 10 p.m.

Details

Clinical and Translational Science Award (UM1 Clinical Trial Optional)

PAR-24-272

Programme: Clinical and Translational Science Award (CTSA) Program

This grant aims to fund Clinical and Translational Science Award (CTSA) Program 'hubs,' which are integrated research and training environments. The core objective is to accelerate the translation of scientific discoveries into improved health outcomes for individuals and communities by fostering scientific and operational innovations in clinical and translational science. The primary target recipients are established medical research institutions and academic health centers, or non-profit research organizations that conduct clinical and translational research. They function as 'hubs' within a national consortium. The size is not defined by employee count but by their capacity to operate as a central institution with integrated research and training environments, potentially collaborating with multiple partner and collaborating institutions. This grant is SECTOR-AGNOSTIC in terms of disease or condition, focusing on the science of translation rather than specific diseases. However, it is research-specific, focusing on clinical and translational science. The geographic scope is the United States (domestic organizations only). Foreign components are allowed, but foreign organizations cannot apply as the prime recipient. Key filtering criteria include: applicant must be an eligible U.S.-based institution type, include a graduate school accredited in clinical/translational science, and commit at least two months of effort per PD/PI. This is a recurring funding opportunity (reissue of PAR-21-293) with multiple annual application deadlines, part of the broader National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) Program.

Funding

Up to 6500000.00 USD

Deadline

Sept. 28, 2027, 9 p.m.

Details

Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia

PAR-25-065

Programme: NIH Research Project Grant

This grant aims to fund research that uncovers the underlying biological, behavioral, and social mechanisms of neuropsychiatric symptoms (NPS) in individuals with Alzheimer's disease (AD) or related dementias (ADRD), with the ultimate goal of developing new treatments. It primarily targets research organizations (such as higher education institutions, nonprofits, for-profit entities including small businesses, and government agencies) capable of conducting advanced biomedical, behavioral, and social sciences research. No specific organizational size is mandated beyond broad categories. This is a SECTOR-SPECIFIC grant focused on health and medical research, particularly neuroscience, aging, and mental health related to AD/ADRD. The geographic scope is global, with U.S. and non-U.S. entities being eligible. Key filtering criteria include a focus on mechanistic research in AD/ADRD-related NPS, the use of the R01 research project grant mechanism (typically not for early-stage ideas), and a requirement for comprehensive data sharing. This is a recurring opportunity, being a reissue of a previous announcement, with multiple submission deadlines until September 2026.

Funding

Up to None USD

Deadline

June 5, 2026, 10 p.m.

Details

Leveraging Europe's Expertise to accelerate Cell Therapy for Type 1 Diabetes

HORIZON-JU-IHI-2025-11-04-two-stage

Programme: Innovative Health Initiative JU Call 11

This grant aims to accelerate cell therapy for Type 1 Diabetes (T1D) by developing standardised tools, methods, and foundational knowledge. The ultimate goal is to facilitate the widespread adoption and integration of these innovative therapies into European healthcare systems, improving patient outcomes and contributing to Europe's leadership in regenerative medicine. The grant is SECTOR-SPECIFIC, primarily targeting the healthcare, biotechnology, pharmaceutical, and medical research sectors. Target recipients are research consortia comprising academic researchers, industry (pharmaceutical, biotech, ICT), healthcare providers, regulatory bodies, and potentially patient organizations. While no specific organization size is mentioned, the consortium requirement implies larger, established entities or collaborations involving them. The geographic scope is Europe-focused, with funding eligibility primarily for entities established in EU Member States and Associated Countries. UK and Canada can participate but are not eligible for funding. Key filtering criteria for applicants include a strong focus on T1D cell therapy, a willingness to engage in European collaboration through a consortium, adherence to the Research and Innovation Action (RIA) scope (emphasizing foundational knowledge and tools over specific product development), and the ability to meet a significant industry contribution requirement. This grant is part of the recurring Horizon Europe / IHI JU Work Programme.

Funding

Up to 8825000.00 EUR

Deadline

April 29, 2026, midnight

Details

Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)

PAR-25-254

Programme: National Institutes of Health (NIH) - National Cancer Institute (NCI) Research Project Grant (R01)

This grant opportunity, PAR-25-254, is seeking mechanistic research to understand how and why expectancy effects occur in the context of cancer symptom management. The core objective is to leverage these effects to improve cancer outcomes and reduce health disparities, particularly for populations historically underrepresented or excluded from biomedical and behavioral research. This is a SECTOR-SPECIFIC grant, focused on cancer research and behavioral science related to health outcomes. It targets a broad range of organizational types, including higher education institutions, non-profits, for-profit organizations (including small businesses), and various government entities, both domestic (US) and international (non-U.S.). This is a recurring funding opportunity, reissued from a previous program, indicating ongoing commitment to this research area.

Funding

Up to None USD

Deadline

Feb. 5, 2026, 5 p.m.

Details

NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)

PAR-25-343

Programme: National Institutes of Health (NIH)

This grant, a Cooperative Agreement (U01) from the National Institute on Deafness and Other Communication Disorders (NIDCD), aims to fund investigator-initiated clinical trials in communication disorders. The core objective is to identify and advance effective interventions for conditions related to hearing, balance, smell, taste, voice, speech, and language, ultimately moving them into standard clinical care. This is a SECTOR-SPECIFIC grant focusing on healthcare research. It targets a wide range of U.S.-based organizations capable of conducting rigorous clinical trials, especially those requiring FDA oversight, establishing formal efficacy, involving higher risks, or having annual direct costs of $700,000 or more. The grant is offered through multiple application cycles over several years, indicating a recurring program.

Funding

Up to None USD

Deadline

Oct. 18, 2027, 5 p.m.

Details

1052 results. Page 4 of 53.